Detalhe da pesquisa
1.
Altered erythropoiesis via JAK2 and ASXL1 mutations in myeloproliferative neoplasms.
Exp Hematol
; 132: 104178, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38340948
2.
Pevonedistat targets malignant cells in myeloproliferative neoplasms in vitro and in vivo via NFκB pathway inhibition.
Blood Adv
; 6(2): 611-623, 2022 01 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-34644371
3.
Cytokine production in myelofibrosis exhibits differential responsiveness to JAK-STAT, MAP kinase, and NFκB signaling.
Leukemia
; 33(8): 1978-1995, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-30718771